NOVATOX

Product Overview

NOVATOX is a South Korean botulinum toxin type A product commercially associated with KG MEDIX Co., Ltd. Available in a 100-unit vial, NOVATOX contains Clostridium botulinum toxin type A formulated with human serum albumin and sodium chloride. The product is supplied as a vacuum-dried white powder in a transparent glass vial, with one vial per standard commercial box.

NOVATOX belongs to the category of botulinum toxin type A neuromodulators. Botulinum toxin type A temporarily inhibits acetylcholine release at susceptible peripheral nerve terminals, reducing neuromuscular signaling and the contraction of affected skeletal muscles.

KG MEDIX identifies NOVATOX as part of its medical aesthetics product portfolio. The company describes its involvement in product development, OEM planning, and international distribution of Korean medical aesthetics products.

Published NOVATOX specifications identify Clostridium botulinum toxin type A at 100 Units per vial, together with 0.5 mg human serum albumin and 0.9 mg sodium chloride.

The product is associated with a Clostridium botulinum strain identified as ATCC 3502. KG MEDIX also describes manufacturing-process development and preliminary biological activity research involving the NOVATOX formulation.

NOVATOX is marketed internationally for professional medical aesthetic applications. However, the product's authorized indications, legal manufacturing entity, and current pharmaceutical registration status must be verified for each destination market.

This TEOSQUARE product page provides professional buyers with information about NOVATOX 100U, including its composition, product characteristics, packaging, pharmacological mechanism, storage considerations, and regulatory requirements.

Key Features

• Botulinum Toxin Type A: Contains Clostridium botulinum toxin type A, a neurotoxic protein that temporarily inhibits acetylcholine release at susceptible peripheral nerve terminals.
• 100 Units per Vial: Each vial contains 100 units of labeled botulinum toxin type A biological potency.
• Albumin-Containing Formulation: Includes 0.5 mg human serum albumin and 0.9 mg sodium chloride as pharmaceutical excipients.
• ATCC 3502 Strain Identification: KG MEDIX identifies Clostridium botulinum ATCC 3502 in its published NOVATOX product information.
• Vacuum-Dried Presentation: Supplied as a dried white powder in a transparent glass vial.
• Single-Vial Packaging: Commercially supplied as one 100U vial per box.
• South Korean Product Origin: Identified as a South Korean product in KG MEDIX's export and commercial product documentation.
• Professional Medical Aesthetics Positioning: Marketed for evaluation by qualified medical professionals and authorized pharmaceutical distributors, subject to applicable national regulations.

Composition & Specifications

NOVATOX contains Clostridium botulinum toxin type A as its principal active ingredient. Human serum albumin and sodium chloride are included as supporting pharmaceutical excipients.

The documented commercial formulation contains 100 units of botulinum toxin type A, 0.5 mg human serum albumin, and 0.9 mg sodium chloride per vial.

Clostridium Botulinum Toxin Type A — 100 Units

Botulinum toxin type A is a neurotoxic protein produced by Clostridium botulinum.

The active neurotoxin interferes with the release of acetylcholine from susceptible peripheral cholinergic nerve terminals. Acetylcholine is a neurotransmitter involved in communication between motor neurons and skeletal muscle fibers.

By inhibiting acetylcholine release, botulinum toxin type A temporarily reduces neuromuscular transmission and muscle contraction.

NOVATOX contains 100 units of Clostridium botulinum toxin type A per vial.

Botulinum toxin potency is expressed in biological activity units rather than milligrams of active protein. The potency of a finished product depends on its manufacturing process and product-specific biological activity assessment.

NOVATOX units should not automatically be regarded as interchangeable with the potency units of BOTOX, Dysport, Xeomin, NABOTA, or other botulinum toxin formulations.

Human Serum Albumin — 0.5 mg

Human serum albumin is a protein commonly used as a stabilizing excipient in biological pharmaceutical formulations.

It can contribute to the stability of protein-based active ingredients during manufacturing, storage, and handling.

Published NOVATOX specifications identify 0.5 mg human serum albumin per 100U vial.

Human serum albumin is derived from human plasma. Its use requires appropriate biological material controls and consideration of relevant product-specific safety information.

Sodium Chloride — 0.9 mg

Sodium chloride is a pharmaceutical excipient used in many injectable formulations.

It contributes to the physicochemical characteristics of the finished preparation.

NOVATOX 100U contains 0.9 mg sodium chloride per vial according to the product specifications published by KG MEDIX.

Clostridium botulinum ATCC 3502

KG MEDIX identifies Clostridium botulinum ATCC 3502 as a strain associated with NOVATOX product development.

Bacterial strain identification is relevant to the characterization and manufacturing history of biological pharmaceutical products.

However, strain identity alone does not establish the purity, potency, clinical effectiveness, or regulatory authorization of the finished product.

The quantitative composition is based on KG MEDIX's published commercial product specifications. The original manufacturer-issued batch documentation and approved product labeling should be used to confirm the formulation of the supplied product.

How NOVATOX Botulinum Toxin Type A Works

NOVATOX contains botulinum toxin type A, which temporarily inhibits acetylcholine release at susceptible peripheral nerve terminals.

This mechanism is characteristic of botulinum toxin type A preparations and provides the pharmacological basis for their effects on neuromuscular transmission.

Normal Neuromuscular Transmission

Under normal physiological conditions, motor neurons release acetylcholine at the neuromuscular junction.

Acetylcholine binds to receptors on skeletal muscle cells, initiating the electrical processes responsible for muscle contraction.

This signaling process depends on the regulated release of neurotransmitter-containing vesicles from nerve terminals.

SNAP-25 and Neurotransmitter Release

Botulinum toxin type A contains an enzymatically active light chain capable of cleaving SNAP-25.

SNAP-25 is a protein involved in the SNARE complex, which is essential for neurotransmitter vesicle fusion.

Cleavage of SNAP-25 interferes with the release of acetylcholine into the neuromuscular junction.

This reduces the transmission of signals from motor nerve terminals to affected skeletal muscles.

Temporary Muscle Relaxation

Reduced acetylcholine release temporarily decreases neuromuscular signaling and muscle contraction.

In appropriately authorized aesthetic applications, botulinum toxin type A can reduce the appearance of dynamic wrinkles associated with repeated facial muscle movement.

Dynamic wrinkles are facial lines that become more visible during expressions such as frowning or smiling.

The presence of botulinum toxin type A in NOVATOX establishes its general pharmacological mechanism but does not independently establish approval for a particular aesthetic indication.

Recovery of Neuromuscular Function

The effects of botulinum toxin type A are temporary.

Neuromuscular function may gradually recover through biological processes involving nerve-terminal recovery and restoration of neurotransmitter release.

The onset, magnitude, and duration of clinical effects depend on the formulation, administration conditions, patient characteristics, and approved indication.

A specific duration of action should not be assigned to NOVATOX solely from clinical studies involving other botulinum toxin products.

These mechanisms are established for botulinum toxin type A as a pharmacological class. They do not demonstrate identical efficacy, safety, potency equivalence, or duration of action between NOVATOX and other commercial botulinum toxin preparations.

Manufacturing & Formulation Characteristics

KG MEDIX identifies NOVATOX as a botulinum toxin type A product associated with its development and international distribution activities.

The company's published technical materials describe bacterial strain identification, biological activity research, manufacturing-process development, and vacuum-dried product presentation.

Vacuum-Dried Formulation

NOVATOX is commercially documented as a vacuum-dried white powder supplied in a transparent glass vial.

Drying is used in certain biological pharmaceutical manufacturing processes to create preparations suitable for storage before professional clinical use.

The physical appearance of a dried preparation does not independently demonstrate its biological potency, stability, or sterility.

Manufacturing-Process Development

KG MEDIX describes manufacturing-process development intended to support the production of botulinum toxin type A.

Its published materials refer to research involving the optimization of manufacturing processes and the development of production facilities.

These statements describe the company's development activities and should not be interpreted as confirmation that every current commercial batch is manufactured at a particular facility.

Company-Reported Purification Research

KG MEDIX publishes analytical information associated with its botulinum toxin development process, including a chromatographic result described in relation to a highly concentrated stock solution.

The company also refers to a figure exceeding 99% in its manufacturing-process materials.

However, the available documentation does not establish that this figure represents a validated 99% purity specification for the finished NOVATOX product.

Consequently, a specific finished-product protein purity percentage should not be assigned to NOVATOX without appropriate manufacturer-controlled analytical evidence.

Preclinical Biological Activity Research

KG MEDIX reports preliminary research involving compound muscle action potential (CMAP) measurements.

CMAP is an electrophysiological measurement used to assess the electrical response of muscle following stimulation of its motor nerve.

The company's research materials describe muscle contraction inhibition following exposure to its botulinum toxin preparation.

These findings provide preliminary biological activity information but do not establish clinical equivalence, interchangeability, or comparable treatment duration between NOVATOX and an approved reference product.

The manufacturing and research characteristics described above are based on KG MEDIX's published development materials. Preclinical activity data, manufacturing permits, and process-related statements are not substitutes for product-specific regulatory approval or completed clinical evidence.

NOVATOX 100U Packaging & Product Presentation

NOVATOX is commercially documented in a 100-unit presentation containing one glass vial per box.

The product is supplied as a vacuum-dried white powder rather than a ready-to-use liquid preparation.

The 100-unit designation represents the labeled biological potency of the toxin preparation in each vial.

It does not represent a liquid volume, a concentration expressed in milligrams, or a recommended administration quantity.

KG MEDIX's official commercial materials document NOVATOX 100U. An additional 200U presentation has not been independently verified from the available company-controlled product information.

Professional buyers should confirm the original product name, potency, batch number, expiration date, responsible legal manufacturer, and applicable regulatory labeling before procurement.

The documented commercial presentation contains one 100U vial per box. Multiple-vial purchasing quantities offered by distributors should not automatically be interpreted as original manufacturer packaging configurations.

Storage & Handling

NOVATOX is a biological product containing botulinum toxin type A. Appropriate temperature-controlled storage and handling are important considerations for maintaining product integrity.

International commercial distributors describe refrigerated storage for NOVATOX, with certain listings specifying a temperature range of 2°C to 8°C.

However, a definitive manufacturer-issued storage specification for the finished commercial presentation has not been independently verified. The original product labeling should therefore take precedence over general distributor information.

• Temperature-Controlled Storage: Follow the validated temperature range stated on the original manufacturer-issued product label.
• Refrigerated Distribution: Commercial suppliers commonly identify refrigeration as a handling requirement; confirm the exact permitted temperature range before transportation.
• Original Packaging: Maintain the product in its original sealed vial and manufacturer packaging.
• Container Integrity: Inspect the vial and packaging for visible damage or evidence of compromised integrity.
• Product Traceability: Verify the labeled potency, lot number, expiration date, responsible manufacturer, and applicable regulatory documentation.
• Professional Handling: Follow the product-specific authorized instructions for preparation, administration, and disposal.

Storage requirements for a prepared botulinum toxin solution may differ from those applicable to an unopened dried preparation.

The appropriate handling period after preparation must be determined from validated product-specific instructions.

A definitive shelf life and manufacturer-validated storage range have not been established from the available primary documentation. Do not assume that NOVATOX has identical stability or storage requirements to another botulinum toxin brand.

Safety & Regulatory Considerations

NOVATOX contains botulinum toxin type A, a potent neuroactive biological substance. Any clinical application requires appropriate medical expertise and compliance with applicable pharmaceutical regulations.

Potential Adverse Reactions

Adverse reactions associated with botulinum toxin type A products may include localized discomfort, swelling, bruising, headache, and unintended weakness of nearby muscles.

Depending on the anatomical area and circumstances of administration, additional effects may include eyelid drooping, facial asymmetry, and other functional changes.

These are known risks associated with the pharmacological class. Their specific incidence for NOVATOX has not been established from independently verified clinical data.

Potential Spread of Toxin Effects

Botulinum toxin products may cause serious adverse reactions if their effects extend beyond the intended treatment area.

Potential complications associated with this drug class include generalized muscle weakness, swallowing difficulties, speech disturbances, and respiratory impairment.

Such reactions may require urgent medical attention.

Contraindications and Precautions

Known hypersensitivity to botulinum toxin type A or relevant formulation components, as well as infection at a proposed administration site, are important considerations for this category of medicines.

Certain neuromuscular conditions and medications affecting neuromuscular transmission may increase the risk of adverse reactions.

NOVATOX contains human serum albumin, and applicable safety information concerning human-derived biological excipients should also be reviewed.

Non-Interchangeable Potency Units

Botulinum toxin biological potency units are product-specific.

NOVATOX 100U should not be considered directly equivalent to 100 units of BOTOX, NABOTA, MEDITOXIN, BOTULAX, or another commercial botulinum toxin preparation.

Similar labeled unit counts do not establish identical biological potency, clinical response, safety characteristics, or duration of effect.

Clinical Evidence Limitations

KG MEDIX has published preliminary research information describing biological activity associated with its NOVATOX development program.

The available information includes nonclinical measurements of muscle responses and references to clinical development activities.

However, these materials do not independently establish completed, adequately controlled clinical trials demonstrating the efficacy and safety of the finished commercial NOVATOX formulation for particular medical or aesthetic indications.

Claims of guaranteed wrinkle reduction, superior durability, lower antibody formation, or clinical equivalence to another botulinum toxin product should therefore not be made without appropriate product-specific evidence.

Regulatory Authorization

KG MEDIX's published materials refer to Korean Good Manufacturing Practice documentation, export-related permissions, and clinical investigational authorization.

These documents concern manufacturing, export, or development activities and do not independently establish marketing authorization for the finished NOVATOX product in every country.

Current product-specific marketing authorization and approved prescribing information in South Korea have not been independently confirmed from the available records.

US FDA approval for NOVATOX has not been established.

Professional buyers should verify the exact product's regulatory registration, legal manufacturing entity, approved indications, import eligibility, prescription requirements, and distribution restrictions before procurement.

This information is intended for professional product identification and commercial evaluation. It does not establish approved clinical indications, provide administration instructions, replace official prescribing information, or authorize distribution outside applicable pharmaceutical regulations.

Frequently Asked Questions